Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

SCOTT MEDICAL'S ISPAN OPHTHALMIC GASES WILL BE MARKETED BY ALCON SURGICAL

This article was originally published in The Gray Sheet

Executive Summary

Alcon Surgical will market Scott Medical's Ispan Ophthalmic gases under an exclusive worldwide agreement between the two firms. Scott Medical's Ispan C3F8 perfluoropropane gas and Ispan SF6 sulfur hexafluoride gas were both approved by FDA Feb. 25 for use as an aid in the treatment of uncomplicated retinal detachment via pneumatic retinopexy. C3F8 is absorbed by the eye six weeks after injection and SF6 in 10 days. The gases were recommended for approval by FDA's ophthalmic devices panel in April 1991 ("The Gray Sheet" April 22, 1991, I&W-3).
Advertisement
Advertisement
UsernamePublicRestriction

Register

MT000420

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel